CBSA announces new board leadership

Thursday May 25, 2017 0 comments Tags: Denver, CBSA, April Giles, Scott Larson, Mark Spiecker

DENVER -- Colorado BioScience Association (CBSA) announced the appointment of Scott Larson as its new chairman of the board of directors.

Larson, senior VP of legal and general counsel for the global medical device innovator and Lakewood-based Terumo BCT, will lead CBSA for a two-year term. Larson replaces outgoing chair Mark Spiecker, who will continue to serve on the CBSA board and executive committee through 2017.CBSA_logoUSE

Joining Larson and Spiecker in executive committee positions are:

Vice Chairman: Ginny Orndorff, director, CID4,
Treasurer: Jim Wilson, partner, E&Y
Secretary: Alan Rudolph, CSU VP for Research
Membership Chair: Dustin Whistler, Forte Commercial Real Estate
Policy Chair: Dan Wittenberg, Snell & Wilmer 

“The Colorado BioScience Association supports our fast-growing sector by focusing efforts on the themes that matter most to our members, including increasing access to capital, highlighting their success stories, and connecting talent within Colorado biosciences,” said Larson.

“I’m proud to work with our board to directly contribute to the vitality of our bioscience sector.”

The 30-person CBSA board of directors is comprised of representatives from the state’s biotechnology, medical device, diagnostic, pharmaceutical, ag bio, digital health, healthcare and research organizations.

Newly appointed board members include:

Frank Segrave, CEO, Silvergate Pharmaceuticals 
Christopher Banas, CEO, Bio2 Medical 
Chris McDonald, VP of Global Biologics – Colorado, AstraZeneca 
Shelley Zelin, VP of Human Resources, Allosource 

“Our newest board members, all from commercial companies, represent a shift in our state’s bioscience sector,” said April Giles, CBSA CEO.

“While Colorado is known for a thriving start-up community, several of our companies are moving from the emerging or mid-stage into the manufacturing stage.

“We’re pleased to welcome leaders from Silvergate Pharmaceuticals, Bio2Medical, AstraZeneca and Allosource to the Colorado Bioscience Association Board of Directors.”

Board members commit to a three-year term and work in partnership with CBSA staff to support the growth of Colorado’s more than 720 bioscience companies.

Names and biographies of the full board of directors are available on the CBSA website.